TriangleNCT02048371 · OUTCOME
Progression-free Survival (PFS), Cohorts A and B, After Crossover.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- up to 3 years
What was measured
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Analysis population: Participants who started on placebo in Cohorts A and B, then crossed over to active drug after progression.
Groups in this outcome
Cohort A: Liposarcoma Crossover
Participants who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Cohort B: Osteosarcoma Crossover
Participants who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
| Group | Source count |
|---|---|
| Cohort A: Liposarcoma Crossover | 15 |
| Cohort B: Osteosarcoma Crossover | 11 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A: Liposarcoma Crossover | 1.68 | Not reported | 0.92 | 5.59 | Not reported |
| Cohort B: Osteosarcoma Crossover | 5.78 | Not reported | 3.55 | NA | The upper limit of the CI is below the level of detection. |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0.92
- upper Limit
- 5.59
- value
- 1.68
- comment
- The upper limit of the CI is below the level of detection.
- group Id
- OG001
- lower Limit
- 3.55
- upper Limit
- NA
- value
- 5.78
- denoms
- counts
- group Id
- OG000
- value
- 15
- group Id
- OG001
- value
- 11
- units
- Participants
- description
- The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
- id
- OG000
- title
- Cohort A: Liposarcoma Crossover
- description
- Participants who started on placebo and crossed over to active drug. Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib Regorafenib: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
- id
- OG001
- title
- Cohort B: Osteosarcoma Crossover
- param Type
- MEDIAN
- population Description
- Participants who started on placebo in Cohorts A and B, then crossed over to active drug after progression.
- reporting Status
- POSTED
- time Frame
- up to 3 years
- title
- Progression-free Survival (PFS), Cohorts A and B, After Crossover.
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice